IPR Tracker: IPR2016-00258 (U.S. Pat. No. 9,051,556) (Green Cross Corp.) – Final Written Decision

Goodwin
Contact

The PTAB issued a Final Written Decision in IPR2016-00258, wherein Petitioner Green Cross Corp. challenged claims  1-3, 16, and 17 of Shire Human Genetic Therapies, Inc.’s U.S. Patent No. 9,051,556.  Green Cross, which is developing a biobetter of Shire’s Elaprase (idursulfase) for Hunter syndrome, had argued that the challenged claims were obvious under 35 U.S.C. § 103 based on a prior art reference, Jin, in view of other prior art.  The Board found that Green Cross failed to carry its burden of showing obviousness because Shire antedated the Jin reference by showing reduction to practice of all claimed elements prior to the critical date of Jin.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Goodwin | Attorney Advertising

Written by:

Goodwin
Contact
more
less

Goodwin on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide
- hide

This website uses cookies to improve user experience, track anonymous site usage, store authorization tokens and permit sharing on social media networks. By continuing to browse this website you accept the use of cookies. Click here to read more about how we use cookies.